Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. (Q38195432)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

review article

1 reference

title

Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

glucocorticoid-induced osteoporosis

10 March 2020

main subject

osteoporosis

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Mark S Cooper

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Hong Zhou

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

1 reference

28 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

59-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Use of oral corticosteroids in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Exogenous and endogenous glucocorticoids in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Mechanisms of glucocorticoid-induced myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoid-induced osteonecrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Morbidity from asthma in relation to regular treatment: a community based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

The impact of oral corticosteroid use on bone mineral density and vertebral fracture

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Inhaled corticosteroid use and bone-mineral density in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Characterization of cells with osteogenic potential from human marrow

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Deletion of mesenchymal glucocorticoid receptor attenuates embryonic lung development and abdominal wall closure.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Mice deficient in 11beta-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Matrix-embedded cells control osteoclast formation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

11β-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Can 11β-Hydroxysteroid Dehydrogenase Activity Predict the Sensitivity of Bone to Therapeutic Glucocorticoids in Inflammatory Bowel Disease?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Endocrine regulation of energy metabolism by the skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Minireview on regulation of intestinal calcium absorption. Emphasis on molecular mechanisms of transcellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoid-induced myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

1 reference

7 January 2021

Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Interventions for preventing falls in older people living in the community

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

The science and therapy of glucocorticoid-induced bone loss.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Corticosteroid osteoporosis: practical implications of recent trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

Selective glucocorticoid receptor modulation maintains bone mineral density in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970045-7

7 January 2021

10.1016/S2213-8587(13)70045-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622268%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference